News from contagionlive.comFollowNews from contagionlive.comSee all of contagionlive.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.We’ve discovered 2 headlines written by contagionlive.com during the past 3 months. We’ve assigned a media bias rating of unknown to contagionlive.com. You can read more about our methodology here. contagionlive.com’s aggregated factuality score is high. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow See all of contagionlive.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources. We’ve discovered 2 headlines written by contagionlive.com during the past 3 months. We’ve assigned a media bias rating of unknown to contagionlive.com. You can read more about our methodology here. contagionlive.com’s aggregated factuality score is high. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about contagionlive.comWhere is contagionlive.com located?contagionlive.com's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: HighHighbyMedia Bias/Fact CheckLearn more about Factuality Ratings.Top contagionlive.com NewsEnsitrelvir's Antiviral Efficacy and Symptom Management in COVID-19While the SCORPIO-HR phase 3 trial did not meet its primary endpoint of sustained symptom resolution, ensitrelvir showed promising results in reducing symptom duration and preventing viral rebound.See the StoryCDC · United StatesFDA approves first RSV vaccine for at-risk adults in their 50s67% Center coverage: 9 sourcesThe Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at higher risk of severe RSV, the company said Friday, making it the first shot greenlit for use in this age group to guard against RSV. Global vaccine and drugmaker GSK asked the FDA in February to expand approval beyond adults 60 and older, citing data showing the immune response in adults vaccinated from this younger age group looked similar. Further trials are planned looking at adults between 18 and 49 years old, GSK said, with results expected in the second half of this year. See the StoryLatest News StoriesMore stories